GRI
$2.36-0.23 (-8.88%)
Market ClosedAs of Mar 20, 8:00 PM UTC
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.
Recent News
Sector Update: Health Care Stocks Climb Late Afternoon
Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index up 1.8% and the Hea
Sector Update: Health Care Stocks Higher Thursday Afternoon
Health care stocks rose Thursday afternoon, with the NYSE Health Care Index up 1.4% and the Health C
GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF
The trial was recommended by the interim analysis committee to proceed as per the plan.